Switch to
More onapp

How to use scorecard? Learn more

Nath Bio-Genes (I) Ltd

NATHBIOGEN
Consumer StaplesAgro Products
SmallcapWith a market cap of ₹421 cr, stock is ranked 1,914
High RiskStock is 3.21x as volatile as Nifty
221.120.66 (-0.30%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

Avg

Can be considered moderately valued vs the market

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Consumer StaplesAgro Products
SmallcapWith a market cap of ₹421 cr, stock is ranked 1,914
High RiskStock is 3.21x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
10.18
PB RatioPB Ratio
0.69
Dividend YieldDiv. Yield
0.90%
Sector PESector PE
56.08
Sector PBSector PB
11.13
Sector Div YldSctr Div Yld
1.29%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Nath Bio-Genes (India) is engaged in hybrid seed business and production, processing and marketing of hybrid and genetically modified (GM) seeds

Financial TrendFinancial statements 

2021202220232024309.23280.21301.91336.7055.65-67.3935.0139.62
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Loss/Duplicate-Share Certificate-XBRL 
Announced OnAug 22, 2024

NATH BIO-GENES (INDIA) LIMITED has informed the Exchange about Loss of share certificates | Download

NATH BIO-GENES (INDIA) LIMITED has informed the Exchange about Loss of share certificates | Download

Clarification - Financial Results 
Announced OnAug 19, 2024
The Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
The Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Cash Dividend 
Ex. DateAug 9, 2024

Final • Div/Share: ₹ 2

See all events